Loading…
Underlying
Underlying Price
$8.36
Type
Put
Strike
8.5
Expiration
Nov 13, 2026
DTE
24d
Moneyness
ITM
Intrinsic
$0.14
IBRX 8.5 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $0.11 | +22.22% | 5 | 355 |
| Oct 30, 2026 | 10d | $0.35 | +75.00% | 33 | 1,052 |
| Nov 6, 2026 | 17d | $0.40 | +21.21% | 115 | 176 |
| Nov 13, 2026 | 24d | $0.45 | -6.25% | 5 | 27 |
| Nov 27, 2026 | 38d | $0.80 | +0.00% | 4 | 3 |
IBRX Nearby Strikes · Nov 13, 2026
| Strike | Last | Change | Vol | Open Int | Moneyness |
|---|---|---|---|---|---|
| 5.5 P | — | — | 0 | 0 | OTM |
| 6 P | $0.20 | -20.00% | 1 | 18 | OTM |
| 6.5 P | $0.05 | -95.15% | 10 | 11 | OTM |
| 7 P | $0.20 | -60.00% | 800 | 1,105 | OTM |
| 7.5 P | $0.28 | -6.67% | 10 | 7 | OTM |
| 8 P | $0.75 | +114.29% | 1 | 66 | OTM |
| 8.5 P | $0.45 | -6.25% | 5 | 27 | ITM |
| 9 P | $0.75 | +25.00% | 4 | 238 | ITM |
| 9.5 P | $1.14 | +26.67% | 20 | 24 | ITM |
| 10 P | $1.05 | -12.50% | 4 | 11 | ITM |
| 10.5 P | $1.60 | +39.13% | 23 | 33 | ITM |
| 11 P | $1.50 | +0.00% | 4 | 2 | ITM |
| 11.5 P | $2.02 | -4.72% | 1 | 5 | ITM |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.